Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

array biopharma

Home/Tag:array biopharma
19 01, 2015

Update: ARRY-520

Tags: , , , |3 Comments

At the American Society of Hematology (ASH) meetings in San Francisco last December, I had a chance to sit down with Selena Rush, Director of Clinical Operations at Array Biopharma.  Array manufactures the promising new myeloma therapy, ARRY-520 (filanesib). I had two reasons to meet with Selena.  First, to get an update on ARRY-520; there

21 07, 2013

Multiple Myeloma News

Tags: , , , , , , , , |0 Comments

The myeloma world doesn't stop turning just because I"m out of town visiting my father.   Let's catch-up on a few important odds 'n ends today. First, I received an email from a reader, questioning the value of the Mayo Clinic retrospective study that Danny Parker and I reported on yesterday.  The issue: the study or

18 06, 2013

Missing in action at ASCO, ARRY-520 hot topic in Europe

Tags: , , , , , |9 Comments

Something was missing from this year's American Society of Clinical Oncology (ASCO) meetings in Chicago this year.  Conspicuously absent was any news about one of the most promising anti-myeloma drugs, ARRY-520.  Why?  Was there a problem with ARRY-520's trial data? Absolutely not!  It turns-out that decision makers at the company that is developing ARRY-520, Array

2 10, 2010

Signal Genetics/Array BioPharma Working Together To Help Individualize Multiple Myeloma Treatment Options

Tags: , , |0 Comments

I didn't get a chance to get you a copy of the latest multliple myeloma release from Signal Genetics last week:Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion DiagnosticsNEW YORK, Sept. 22 /PRNewswire/ -- Signal Genetics, a privately held predictive genetic testing company focused on oncology, today